Upper gastrointestinal bleeding (UGIB) is a common problem with an annual incidence of approximately 80 to 150 per 100,000 population, with estimated mortality rates between 2% to 15%. UGIB is classified as any blood loss from a gastrointestinal source above the ligament of Treitz. It can manifest as hematemesis (bright red emesis or coffee-ground emesis), hematochezia, or melena. Patients can also present with symptoms secondary to blood loss, such as syncopal episodes, fatigue, and weakness. UGIB can be acute, occult, or obscure.
From the possible etiologies of UGIB, Peptic Ulcer disease (PUD) accounts for 40% to 50% of the cases. Of those, the majority is secondary to duodenal ulcers (30%). PUD can be associated with NSAIDs, Helicobacter pylori, and stress-related mucosal disease.
Aside from PUD, erosive esophagitis accounts for 11%, duodenitis for 10%, Varices 5% to 30% (depending if the population studied have a chronic liver disease), Mallory-Weiss tear 5% to 15% and vascular malformations for 5%.
UGIB accounts for 75% of all acute gastrointestinal (GI) bleeding cases. Its annual incidence is approximately 80 to 150 per 100,000 population. Patients on long-term, low-dose aspirin have a higher risk of overt UGIB compared to placebo. When aspirin is combined with P2Y12 inhibitors such as clopidogrel, there is a two-fold to three-fold increase in the number of UGIB cases. When a patient requires triple therapy (i.e., aspirin, P2Y12 inhibitor and vitamin K antagonist), the risk of UGIB is even higher.
During history taking, attention should be given to comorbidities. A detailed review of current medications should be performed, and patients should be directly asked about the use of NSAIDs, antiplatelet drugs, aspirin, or anticoagulants. Also, it is important to get a detailed social history regarding alcohol use.
The clinical presentation can vary but should be well-characterized. Hematemesis is the overt bleeding with vomiting of fresh blood or clots. Melena refers to dark and tarry-appearing stools with a distinctive smell. The term "coffee-grounds" describes gastric aspirate or vomitus that contains dark specks of old blood. Hematochezia is the passage of fresh blood per rectum. The latter is usually a reflection of lower gastrointestinal bleeding (LGIB) but may be seen in patients with brisk UGIB.
Patients may also present with syncope or orthostatic hypotension if bleeding is severe enough to cause hemodynamic instability.
One should also pay attention to the patient's vital signs. Orthostatic vital signs should also be documented. In a comprehensive exam, search for evidence of chronic liver diseases such as palmar erythema, spider angiomas, gynecomastia, jaundice, and ascites. These features may give clues to the etiology of the bleeding (i.e., variceal bleeding).
Initial laboratory work must include a complete blood cell count (CBC) to look for current levels of hemoglobin, hematocrit, and platelets. A low MCV can point towards chronic blood loss and iron deficiency anemia. Chemistry should also be evaluated. Elevated BUN or elevated BUN/Creatinine can also be indicative of UGIB. Coagulation panel should also be checked.
There are few scoring systems designed to predict which patients will likely need intervention and also to predict rebleeding and mortality. The Rockall score was designed to predict rebleeding and mortality and includes age, comorbidities, the presence of shock, and endoscopic stigmata. A pre-endoscopic Rockall is also available and can be used to stratify patient's risk for rebleeding and mortality even before the endoscopic evaluation. When the Rockall score is used, patients with two or fewer points are considered low risk and have a 4.3% probability of rebleeding and 0.1% mortality. In contrast, patients with a score of six or more have a rebleeding rate of 15% and mortality of 39%.
Another scoring system that is traditionally used in UGIB is the Blatchford Score. This scoring system was designed to predict the need for intervention. It includes hemoglobin levels, blood pressure, presentation of syncope, melena, liver disease, and heart failure. A score of six or higher is associated with a greater than 50% risk of needing an intervention.
If the patient is suspected of having UGIB, endoscopy (EGD) must be performed to identify the cause and potentially treat the source of bleeding. Multiple studies have tried to identify the best timing to perform endoscopy. Until now, there is no evidence that emergent EGD is superior to routine EGD (done in 24 to 48 hours). The American College of Gastroenterology continues to recommend that all patients with UGIB should undergo endoscopy within 24 hours of admission, following resuscitative efforts to optimize hemodynamic parameters and other medical problems. Per American College of Gastroenterology recommendations, endoscopy within 12 hours should be considered for all patients with higher risk clinical features (e.g., tachycardia, hypotension, bloody emesis or nasogastric aspirate in the hospital) to potentially improve clinical outcomes.
Patients must have a minimum of two large-bore peripheral access catheters (at least 18-gauge). Intravenous fluids should be administered to maintain adequate blood pressure and hemodynamic stability. If patients are not able to protect their airways or have ongoing severe hematemesis, elective endotracheal intubation is advised.
Blood transfusions should be given to target a hematocrit above 20%, with a hematocrit above 30% targeted in high-risk patients, such as the elderly and patients with coronary artery disease. There is no evidence that higher targets for hematocrit goals should be sought as that higher targets can even be deleterious.
Proton pump inhibitors (PPI) are used to treat patients with nonvariceal UGIB. The use of antacids has been shown to alter the natural history of patients with acute upper GI bleeding. Patients with significant bleeding should be treated with an 80-mg bolus of PPI followed by a continuous infusion. The typical duration is 72 hours for patients with high-risk lesions visualized on EGD. If endoscopy was normal or only revealed low-risk lesion, PPI infusion can be discontinued and patient switch to a daily twice a day infusion or even to oral PPIs.
Octreotide, a somatostatin analog, is a medication used when variceal bleeding is suspected. It is given as an intravenous bolus of 20 mcg to 50 mcg, followed by a continuous infusion at a rate of 25 mcg to 50 mcg per hour. Its use is not recommended in patients with acute nonvariceal upper GI bleeding, but it can be used as adjunctive therapy in some cases. Its role is limited to settings in which endoscopy is unavailable or as a means to help stabilize patients before definitive therapy can be performed.
Endoscopic intervention might be warranted depending on the findings during the upper endoscopy. If a patient has an ulcer with a clean base, no intervention is needed. However, if a bleeding vessel is visualized or there is stigmata of recent bleeding, therapeutic options might include thermal coagulation to achieve hemostasis, local injection of epinephrine or use of clips. A combination of these methods might be needed based on the severity of the lesions.
Management of the patient presenting with UGIB should always follow a step-wise approach. The first step is to assess the hemodynamic status and initiate resuscitative efforts as needed (including fluids and blood transfusions). Patients should be risk stratified based on their initial presentation, hemodynamic status, comorbidities, age, and initial laboratory tests. There are several scoring systems available, with the most commonly used being the Rockall and Blatchford scores. Upper endoscopy should be offered within 24 hours to help diagnose the source of bleeding and help further guide management if needed.
If a bleeding ulcer is found to be the culprit lesion, efforts should be taken to prevent recurrence of bleeding. If the patient is found to have H. pylori, eradication should be a target. If NSAIDs were likely the cause of the bleeding, they should be stopped, and if absolutely needed, alternative agents such as COX-2-selective NSAID plus a PPI should be used. Patients with established cardiovascular disease who require aspirin or other antiplatelet agents should be on PPI therapy and generally can have antiplatelet therapy reinstituted after bleeding ceases (ideally within 1 to 3 days and certainly within 7 days).
The diagnosis and management of a UGIB is with a multidisciplinary team that includes the emergency department physician, gastroenterologist, surgeon and an internist. The initial steps in resuscitation should follow the ATLS protocol. There are several scoring systems available, with the most commonly used being the Rockall and Blatchford scores. Upper endoscopy should be offered within 24 hours to help diagnose the source of bleeding and help further guide management if needed.
The natural history of patients who are treated with endoscopic therapy is that 80% to 90% of patients will have permanent control of their bleeding. However, 10% to 20% will rebleed. Patients who rebleed should have a second endoscopic procedure attempted. If bleeding persists despite endoscopic intervention or source of bleeding can not be identified, other modalities such as angiography or surgery should be considered.
|||Perisetti A,Kopel J,Shredi A,Raghavapuram S,Tharian B,Nugent K, Prophylactic pre-esophagogastroduodenoscopy tracheal intubation in patients with upper gastrointestinal bleeding. Proceedings (Baylor University. Medical Center). 2019 Jan; [PubMed PMID: 30956574]|
|||Kamboj AK,Hoversten P,Leggett CL, Upper Gastrointestinal Bleeding: Etiologies and Management. Mayo Clinic proceedings. 2019 Apr; [PubMed PMID: 30947833]|
|||Fouad TR,Abdelsameea E,Abdel-Razek W,Attia A,Mohamed A,Metwally K,Naguib M,Waked I, Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators. Journal of gastroenterology and hepatology. 2019 Mar 14; [PubMed PMID: 30937995]|
|||Stanley AJ,Laine L, Management of acute upper gastrointestinal bleeding. BMJ (Clinical research ed.). 2019 Mar 25; [PubMed PMID: 30910853]|
|||Cooper AS, Interventions for Preventing Upper Gastrointestinal Bleeding in People Admitted to Intensive Care Units. Critical care nurse. 2019 Apr; [PubMed PMID: 30936135]|
|||Sehested TSG,Carlson N,Hansen PW,Gerds TA,Charlot MG,Torp-Pedersen C,Køber L,Gislason GH,Hlatky MA,Fosbøl EL, Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. European heart journal. 2019 Mar 9; [PubMed PMID: 30851041]|
|||Mocker L,Hildenbrand R,Oyama T,Sido B,Yahagi N,Dumoulin FL, Implementation of endoscopic submucosal dissection for early upper gastrointestinal tract cancer after primary experience in colorectal endoscopic submucosal dissection. Endoscopy international open. 2019 Apr; [PubMed PMID: 30931376]|
|||[Guidelines for the diagnosis and treatment of acute non-variceal upper gastrointestinal bleeding (2018, Hangzhou)]. Zhonghua nei ke za zhi. 2019 Mar 1; [PubMed PMID: 30803174]|
|||Bai Y,Li ZS, [Standardize the diagnosis and treatment of acute non-variceal upper gastrointestinal bleeding based on the update guidelines]. Zhonghua nei ke za zhi. 2019 Mar 1; [PubMed PMID: 30803170]|
|||Jung K,Moon W, Role of endoscopy in acute gastrointestinal bleeding in real clinical practice: An evidence-based review. World journal of gastrointestinal endoscopy. 2019 Feb 16; [PubMed PMID: 30788026]|
|||Sverdén E,Markar SR,Agreus L,Lagergren J, Acute upper gastrointestinal bleeding. BMJ (Clinical research ed.). 2018 Oct 25; [PubMed PMID: 30361444]|
|||Saleem S,Thomas AL, Management of Upper Gastrointestinal Bleeding by an Internist. Cureus. 2018 Jun 25; [PubMed PMID: 30155380]|
|||Savarino V,Marabotto E,Zentilin P,Furnari M,Bodini G,De Maria C,Pellegatta G,Coppo C,Savarino E, The appropriate use of proton-pump inhibitors. Minerva medica. 2018 Oct; [PubMed PMID: 29856192]|
|||Sung JJ,Chiu PW,Chan FKL,Lau JY,Goh KL,Ho LH,Jung HY,Sollano JD,Gotoda T,Reddy N,Singh R,Sugano K,Wu KC,Wu CY,Bjorkman DJ,Jensen DM,Kuipers EJ,Lanas A, Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018 Oct; [PubMed PMID: 29691276]|
|||Chatten K,Purssell H,Banerjee AK,Soteriadou S,Ang Y, Glasgow Blatchford Score and risk stratifications in acute upper gastrointestinal bleed: can we extend this to 2 for urgent outpatient management? Clinical medicine (London, England). 2018 Mar; [PubMed PMID: 29626014]|
|||Riha HM,Wilkinson R,Twilla J,Harris LJ Jr,Kimmons LA,Kocak M,Van Berkel MA, Octreotide Added to a Proton Pump Inhibitor Versus a Proton Pump Inhibitor Alone in Nonvariceal Upper-Gastrointestinal Bleeds. The Annals of pharmacotherapy. 2019 Feb 25; [PubMed PMID: 30803243]|
|||Hajiagha Mohammadi AA,Reza Azizi M, Prognostic factors in patients with active non-variceal upper gastrointestinal bleeding. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology. 2019 Mar; [PubMed PMID: 30770260]|